Unlike other bacterial ClpP systems, mycobacterial ClpP1P2 complex is essential 20 for mycobacterial survival. The functional details of Mycobacterium tuberculosis (Mtb) 21 ClpP1P2 remains largely elusive and selectively targeting ClpP of different species is a 22 big challenge. In this work, cediranib was demonstrated to significantly decrease the 23 activity of MtbClpP1P2. By solving the crystal structure of cediranib-bound 24 MtbClpP1P2, we found that cediranib dysregulates MtbClpP1P2 by interfering with 25 handle domain of the equatorial region of MtbClpP1, indicating that the inter-ring 26 dynamics are crucial for its function. This finding provides direct evidence for the 27 notion that a conformational switch in the equatorial handle domain is essential for ClpP 28 activity. We also present biochemical data to interpret the distinct interaction pattern 29 and inhibitory properties of cediranib toward MtbClpP1P2. These results suggest that 30 the variable handle domain region is responsible for the species-selectivity of cediranib, 31 which suggests the equatorial handle domain as a potential region for screening 32 pathogen-specific ClpP inhibitors. 33 Introduction 34 Caseinolytic protease ClpP, a widely conserved self-compartmentalizing serine 35 protease in bacteria, plays essential roles in protein metabolism and regulates diverse 36 physiological functions including cell motility, genetic competence, cell differentiation, 37 sporulation, and virulence, and is thus an attractive target for antibiotic development[1-38 8]. Notably, ClpP is an novel drug target for which both inhibition and activation result 39 in an attenuated or lethal phenotype in many pathogens; thus agonists and antagonists 40 Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1 3 / 42 aimed at the ClpP system represent promising drug candidates for further evaluation[9, 41 10]. The ClpP enzyme of Mycobacterium tuberculosis (MTB), MtbClpP1P2, exerts its 42 proteolytic function by a heterotetramer of two protein subunits, ClpP1 and ClpP2[11, 43 12]. Moreover, encoding genes of subunits ClpP1 and ClpP2, have been shown to be 44 essential genes for MTB survival and the deletion of either gene causes bacterial 45 death[13]. A panel of MtbClpP1P2 inhibitors have been reported and they can be 46 classified into two categories depending on their action modes. The first kind of small 47 molecules act on the catalytically active center, covalently modifying the serine 48 residues of the active sites of two subunits of MtbClpP1P2, including bortezomib, 49 boron-containing analogues and beta lactones[14-17]. The second kind of inhibitors act 50 on the chaperone protein (ClpX/ClpC1) binding site that competitively binds to the 51 surface of the ClpP2 subunit. Representative molecules of this category are ADEP and 52 its analogs[12]. Since the chaperones binding L/IGF region of ClpP2 subunit is highly 53 conserved, as with the inhibitor of the MtbClpP1P2 catalytic center[18], the ADEP 54 compounds are nonselective as well. As we know, the off-target effects may bring 55 severe side effects during drug development. Thus it is desirable to find novel binding 56 pocket or selective inhibitors targeting MtbClpP1P2 to avoid the potential adverse 57 effects of nonselective ones. In this work, we demonstrate that cediranib, an orally 58 available vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitor, is able to 59 inhibit MtbClpP1P2 peptidase activity. We solved the crystal structure of MtbClpP1P2 60 in complex with an agonist peptide and cediranib, and present details of the inhibitory 61 mechanism. Unlike other ClpP inhibitors, cediranib dysregulates MtbClpP1P2 by 62 Inhibiting ClpP1P2 by addressing the equatorial handle domain of ClpP1 4 / 42
To validate the antibacterial activity of cediranib, we carried out growth inhibition 85 assays on several pathogenic bacteria. As Table 1 and Table 2 with an MIC value of 16 μg/mL. Therefore, cediranib exhibits species-selectivity in 91 suppressing pathogen growth. Next, we performed peptidase assay on human ClpP 92 (hClpP) to estimate the toxicity of cediranib to human mitochondria. As shown in Table   93 1 and S2 Fig, cediranib displayed weak inhibition of hClpP activity compared to 94 MtbClpP1P2, with a selectivity index >10. 95 To gain insights into the inhibitory mechanism of cediranib, we purified and 96 crystallized MtbClpP1P2 in complex with cediranib and benzoyl-Leu-Leu (Bz-LL). 97 The crystals belonged to space group C121 and diffracted to 2.7 Å resolution. The 98 structure was determined by molecular replacement using the previously solved 99 MtbClpP1P2 structure (PDB code 5DZK) as a search model, and the final model was 100 refined to an Rfactor of 20.02% (Rfree =24.33%) (Table 3 ) [19] . The asymmetric unit 101 has one hetero-tetradecameric complex structure composed of heptameric ClpP1 and more compact pore, where α5 moves closer to α3 and the large side chains of Met160 139 and Phe83 restrict accessibility to this pocket, making cediranib unable to bind to 140 MtbClpP2 (Fig 3D) . 141 Unlike the peptidyl inhibitors that occupy the S1-S3 subsites of ClpP [27] , 142 cediranib does not directly interact with the active site, but interferes with the dynamic 143 handle region, which was proposed to be responsible for product release [21, 28] (Fig 144 3C and 3E). Though a small channel in the variable handle region of MtbClpP1 was 145 observed in ADEP-MtbClpP1P2 complex in previous study [12] , we firstly 146 demonstrated this small channel could be occupied by a small molecule, herein 147 cediranib, and be employed to realize MtbClpP selectivity. As Fig 3F illustrates , the 148 cediranib-binding pocket is formed by α5 (residues Gln142-Glu149), α3 (residues 149 Ile71-Ala76) and three short β-sheets (βD, βF, βH) from the neighboring ClpP1 subunit.
It is worth noting that α5 is the major part of the handle domain. 151 Molecular dynamics simulation studies revealed cediranib interferes the 152 conformational changes of MtbClpP1 153 Previous molecular dynamics simulation studies on SaClpP revealed that α5 154 adopts a kinked conformation by breaking the helix at residue Lys145 (corresponding 155 to Val145 in MtbClpP1) [24] . During the reaction cycle, the handle domain undergoes 156 an unfolding/refolding process, allowing the whole cylindrical ClpP barrel to adopt 157 extended, compact and compressed states [23, 24, [29] [30] [31] . In order to analysis the effect 158 of cediranib on the dynamic transition of handle domain, we performed a 500-ns MD terminal part of helix E (residues 133-158) underwent a helical unfolding/refolding 167 process. In the absence of cediranib, the N-terminal part (residues 133-137) in chain B 168 primarily adopted turn structure in 0-350 ns. Then, residues 133-154 adopted coil , turn 169 and 3-10Helix structures. In chain M, residues 143-147 mainly adopted turn structure. 170 With binding of cediranib, the N-terminal part(residues 133-137) of chain B adoped 171 coil and turn strcture in the initial stage (0-300 ns). Subsequently(300-500ns), these residues gradually readopted some 3-10Helix and α-helix. By contrast to chain B, chain 173 M was much more unstable, particularly at 250ns, most α-helix structure adopted turn 174 and coil (S3B Fig and S3D Fig) . To identify the most significant motions of handle 175 domain of MtbClpP1 dimer induced by cediranib, we performed PCA using the MD 176 trajectory [24] . As shown in S3E Fig and S3F Fig, during Mutagenesis and functional analysis of the cediranib-binding site 184 As we known, the ClpPs from different species share high sequence similarity 185 (55.0-90.9%) and conserved overall structure ( Fig 4A) . Consistently, the general and 186 critical gating mechanism of ClpP requires the handle domain to preserve its structural 187 integrity [29] 195 To investigate the residues in the cediranib-binding pocket, we introduced 196 different mutations in relevant sites based on sequence alignment ( Fig 4B and Table 4 ). 197 Consistent with the importance of the equatorial pore and handle domain, most site-198 directed mutations in the selected sites decreased or abolished MtbClpP1P2 activity. 199 Considering Ile71, Met75, Ile146 and Trp174, even when residues with similar side 200 chains were substituted in those sites, the enzyme activity was not retained, suggesting 201 there are constraints on both residue size and chemical properties to maintain the local 202 structural integrity and flexibility (Table 4 and Fig 4C) . 203 An electrostatic interaction between two MtbClpP1 subunits (Arg119-Gln142) 204 ( Fig 3F) seems to be an important factor mediating the side pore gating, because any 205 substitution that changed the charge properties of either site resulted in reduced or 206 abolished activity. In contrast, sites Met95 and Glu149 of MtbClpP1 exhibit various 207 levels of tolerance to mutation. In particular, Met95Gln and Glu149Leu variants retain 208 activity and have altered sensitivity of MtbClpP1P2 to cediranib, providing a structural 209 basis for the specific recognition between cediranib and MtbClpP1 (Table 4 ).
210

Discussion
211
ClpP represents a unique type of serine protease complex responsible for the 212 proteolysis of damaged or misfolded proteins. Because it plays critical roles in the 213 regulation of infectivity and virulence of many bacterial pathogens and is involved in 214 various human diseases, interfering with ClpP activity has been evaluated as a potential therapeutic strategy in the treatment of different ailments [32] . In-depth understanding 216 of the mechanism of ClpP reaction and regulation is crucial for development of 217 chemotherapeutic agents that target this protein. The importance of the dynamic 218 equatorial region in ClpP has long been recognized [21] [22] [23] [24] [29] [30] [31] . 219 As the first identified inhibitor targeting flexible handle region of ClpP, cediranib 220 shows a distinct inhibitory mechanism. The cediranib-bound MtbClpP1P2 complex 221 structure provides valuable evidence to support the important roles of equatorial handle 222 domain for ClpP function [21][26] . Compared with the highly conserved critical residues 223 in the N-terminal region of α5 (Ile136, Ile138, and Ala140 in MtbClpP1) ( Fig 4C) , 224 residues participating in cediranib binding are relatively diverse among different ClpP 225 homologs, leading to a substantial variation in the size of the binding pockets near to 226 the side pores, which suggests this mechanism could be employed for pathogen-227 selective ClpP inhibitor development.
228
Materials and Methods
229
Bacterial strains and culture conditions. Escherichia coli DH5α and BL21 (DE3) 230 were cultured at 37°C in Luria broth (LB) and LB-agar plates. DNA encoding M. 231 tuberculosis ClpP1 and ClpP2 (spanning residues 7-200 and 13-214, respectively) was 232 cloned into a pRSF-Duet vector preceded by an N-terminal His6-SUMO tag 233 (Novagen) [11, 12] . Full-length EcClpP, SaClpP, PaClpP1 and the hClpP gene without 234 its mitochondrial targeting sequence (residues Met1-Pro57) were also respectively 235 cloned into pRSF-Duet preceded by an N-terminal His6-SUMO tag [33] [34] [35] . PCR was 236 performed with PrimeSTAR ® max DNA polymerase (Takara) and Ex Taq ® polymerase (Takara). The plasmids carrying distinct ClpP genes were transformed into Escherichia 238 coli BL21 (DE3) cells (TransGen Biotech). The plasmids and primers used in this study 239 are listed in Appendix Table S1 and Appendix Table S2 . 240 Protein expression and purification. M. tuberculosis ClpP1 (residues 7-200) and 241 ClpP2 (residues 13-214) with N-terminal His6-SUMO tags were expressed and purified 242 as described, with minor modifications [11, 12, 14] . In short, ClpP1 and ClpP2 were Compound screening. The peptidase activity of MtbClpP1P2 was monitored at 30°C 260 in black 96-well plates, as described [11, 14] . After peptide bond cleavage, the 261 fluorophore 7-amino-4-methylcoumarin of the fluorogenic substrate Z-Gly-Gly-Leu-262 AMC is liberated and can be quantified. Briefly, each well contained 100 μM 263 fluorogenic peptide, 0.5 μM tetradecamer ClpP1P2, and 2 mM Bz-LL in 80 μL of buffer 264 containing 50 mM phosphate buffer, pH 7.6, 300 mM KCl, 5 mM MgCl2 and 5% 265 glycerol. Substrate cleavage was monitored using an all-in-one microplate reader (Gen5; 266 BioTek) by exciting at 380 nm and following the increase in fluorescence emission at 267 460 nm. The deviation of fluorescence value in at least two independent measurements 268 was ≤5%. The screening assay was carried out in 96-well format as described above, 269 and about 2600 compounds were screened at 100 µM. Positive (bortezomib) and Data collection and structure determination. The X-ray data were collected with a 304 CCD camera at station BL-19U of the Shanghai synchrotron radiation facility (SSRF), 305 Shanghai, China. The diffraction data were indexed, integrated, and scaled using the 306 HKL2000 program suite [37] . The process of structure building and refinement was 307 monitored using the COOT and PHENIX suites [38, 39] . The PDB code for the co-308 crystal structure of cediranib with MtbClpP1P2 (resolution 2.7 Å) is 6IW7. MtbClpP1P2 dimer was solvated in a rectangular water box of TIP3P and neutralized 332 with Na+ ions. The periodic boundary conditions were setup with all the solvents 10 Å 333 away from the solutes. The protein were parameterized using the AMBER FF99SB 334 force field[43] and the ligands were parameterized using the GAFF force filed [44] . 335 Energy minimization was performed firstly to remove the local atomic collision in the 336 systems and the combination of the descent steepest with conjugated gradient method 337 was adopted in the process. In the NVT ensemble, the systems were heated from 0 to 
